Stride Health is an early-stage healthcare IT company developing a multi-carrier, private health insurance marketplace for the individual segment.
Sector: Healthtech + Services
TraceLink
TraceLink the world’s largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes.
US HealthVest
US HealthVest provides specialized, high quality psychiatric care, including substance abuse treatment, through a broad range of inpatient and outpatient programs.
Lumere
Lumere (formerly Procured Health) is an organization comprised of clinicians, researchers, pharmacists and strategic thought leaders focused on helping health systems eliminate unwarranted clinical variation and cut unnecessary costs—specifically related to device and drug selection and utilization. This company was acquired by Global Healthcare Exchange (GHX) in 2020.
Liazon
Liazon is a provider of web-based private benefits exchanges to small and medium-sized businesses. Liazon was acquired by Towers Watson in 2013.
Kyruus
Kyruus uses the science of data-driven clinical matching to ensure that patients are being matched to the right provider and enabling healthcare systems to coordinate care delivery across their provider networks.
Iora Health
Iora Health is building a different kind of health system to deliver high impact, relationship based care. Iora Health was acquired by One Medical in September 2021.
Carl Byers
Carl Byers brings significant operating experience in healthcare IT to his role as Partner. He was on the founding team at athenahealth, Inc. (Nasdaq: ATHN), where he served as Chief Financial Officer from 1997 to 2010. Carl was responsible for the company’s finance, legal and corporate technology teams and served as a key advisor to the CEO. When athenahealth was a private company, he built the company’s financial systems and led seven rounds of equity and subordinated debt financing. Carl led athenahealth’s 2007 Initial Public Offering, which the Wall Street Journal named as the year’s most successful. In his tenure, he also held various operational roles at different times. Prior to the founding of athenahealth, Carl was a Senior Consultant in Booz, Allen & Hamilton’s New York office, where he worked in the financial services and health insurance industries. Carl teaches finance at Harvard’s Chan School of Public Health where he is an Adjunct Lecturer on Health Policy and Management. He was appointed by Governor Charlie Baker to the Massachusetts Digital Health Council.
Carl holds a B.A. from Wesleyan and is a graduate of the Harvard Kennedy School’s Mid-Career Masters in Public Administration program.
Jon Lim
Jon Lim is a Managing Partner who joined F-Prime in 2011 to launch our dedicated efforts in Healthtech + Services. His investments include F-Prime’s investments in Liazon (acquired by Towers Watson), PatientPing (acquired by Appriss Heath, now Bamboo Health), VitalWare (acquired by Health Catalyst), Artemis Health (acquired by Nomi Health), Lumere (acquired by Global Healthcare Exchange), Blue Rabbit (acquired by Wedgewood Pharmacy), Protenus (acquired by Bluesight), Benchling, BenchSci, Centivo, Equip Health, Kyruus, NOCD, OncoveryCare, Proximie, Rippl, TraceLink, US HealthVest and WelbeHealth. Jon was previously a Principal at Polaris Partners, where he was part of the teams that led investments in Phytel (acquired by IBM), Egnyte, Recurly, and Ocular Therapeutix (NASDAQ: OCUL). Jon began his investing career in 2002 as an Associate at Summit Partners, where his investments include MDVIP (acquired by Procter & Gamble) and Diagnostic Hybrids (acquired by Quidel). Jon also worked previously at Medtronic in their cardiac rhythm and disease management business.
Jon holds an M.B.A. from Harvard Business School and an A.B. in East Asian Studies from Harvard College, where he graduated magna cum laude.
Stephen Knight, M.D.
Stephen Knight joined F-Prime in 2003 where he serves as President and Senior Managing Partner. He has worked in the pharmaceutical and biotechnology industries for over 30 years and invests broadly across healthcare. Steve serves on the Board of Directors of Atalanta Therapeutics, Leyden Labs, Paradigm, Quantum Circuits, Inc. (QCI), Skyline Therapeutics, and Xaira Therapeutics. Steve previously served on the boards of several private and public health care companies including Beam Therapeutics (NASDAQ: BEAM), Blueprint Medicines (NASDAQ: BPMC), Denali Therapeutics (NASDAQ: DNLI), FoldRx Pharmaceuticals (acquired by Pfizer), Innovent Biologics (1801.HK), Iora Health (acquired by One Medical), Ironwood Pharmaceuticals (NASDAQ: IRWD), NextWave Pharmaceuticals (acquired by Pfizer), Prime Medicine (NASDAQ: PRME), Respivert, Ltd (acquired by J&J), Sana Biotechnology (NASDAQ: SANA), and Semma Therapeutics (acquired by Vertex).
Prior to joining F-Prime, Steve held various senior management roles in private and public biotechnology and consulting companies. He also was a researcher at AT&T Bell Laboratories, the National Institutes of Health, and Yale University. He holds an M.D. from the Yale University School of Medicine, an M.B.A. from the Yale School of Organization and Management and received a B.S. in biology from Columbia University, graduating summa cum laude and Phi Beta Kappa.